Comparative Pharmacology
Head-to-head clinical analysis: ORSYTHIA versus ORTHO NOVUM 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORSYTHIA versus ORTHO NOVUM 10 11 28.
ORSYTHIA vs ORTHO-NOVUM 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal aromatase inhibitor that selectively and reversibly inhibits aromatase, the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in tissues.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
400 mg orally twice daily
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
None Documented
None Documented
Terminal half-life ~12 hours (range 10-14 h); prolonged in renal impairment (up to 24-30 h).
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Primarily renal (≥90% as unchanged drug); <5% biliary/fecal.
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive